PMC:7600245 / 41455-42003 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T155","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"T156","span":{"begin":257,"end":265},"obj":"Disease"},{"id":"T157","span":{"begin":496,"end":504},"obj":"Disease"}],"attributes":[{"id":"A155","pred":"mondo_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A156","pred":"mondo_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A157","pred":"mondo_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Currently, selinexor is being evaluated in at least two phase 2 randomized trials in the U.S. in COVID-19 patients. One is to evaluate the activity, safety and reduction in mortality of two regimens of low-dose selinexor in patients with moderate or severe COVID-19 (NCT04355676, n = 80) and the other is to evaluate the activity of low-dose selinexor and its effect on the clinical recovery, viral load, length of hospitalization, and rate of morbidity and mortality in participants with severe COVID-19 compared to placebo (NCT04349098, n = 230)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T380","span":{"begin":139,"end":147},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T381","span":{"begin":321,"end":329},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Currently, selinexor is being evaluated in at least two phase 2 randomized trials in the U.S. in COVID-19 patients. One is to evaluate the activity, safety and reduction in mortality of two regimens of low-dose selinexor in patients with moderate or severe COVID-19 (NCT04355676, n = 80) and the other is to evaluate the activity of low-dose selinexor and its effect on the clinical recovery, viral load, length of hospitalization, and rate of morbidity and mortality in participants with severe COVID-19 compared to placebo (NCT04349098, n = 230)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T311","span":{"begin":0,"end":115},"obj":"Sentence"},{"id":"T312","span":{"begin":116,"end":548},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, selinexor is being evaluated in at least two phase 2 randomized trials in the U.S. in COVID-19 patients. One is to evaluate the activity, safety and reduction in mortality of two regimens of low-dose selinexor in patients with moderate or severe COVID-19 (NCT04355676, n = 80) and the other is to evaluate the activity of low-dose selinexor and its effect on the clinical recovery, viral load, length of hospitalization, and rate of morbidity and mortality in participants with severe COVID-19 compared to placebo (NCT04349098, n = 230)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1250","span":{"begin":106,"end":114},"obj":"Species"},{"id":"1251","span":{"begin":224,"end":232},"obj":"Species"},{"id":"1252","span":{"begin":471,"end":483},"obj":"Species"},{"id":"1253","span":{"begin":211,"end":220},"obj":"Chemical"},{"id":"1254","span":{"begin":342,"end":351},"obj":"Chemical"},{"id":"1255","span":{"begin":97,"end":105},"obj":"Disease"},{"id":"1256","span":{"begin":173,"end":182},"obj":"Disease"},{"id":"1257","span":{"begin":257,"end":265},"obj":"Disease"},{"id":"1258","span":{"begin":458,"end":467},"obj":"Disease"},{"id":"1259","span":{"begin":496,"end":504},"obj":"Disease"}],"attributes":[{"id":"A1250","pred":"tao:has_database_id","subj":"1250","obj":"Tax:9606"},{"id":"A1251","pred":"tao:has_database_id","subj":"1251","obj":"Tax:9606"},{"id":"A1252","pred":"tao:has_database_id","subj":"1252","obj":"Tax:9606"},{"id":"A1253","pred":"tao:has_database_id","subj":"1253","obj":"MESH:C585161"},{"id":"A1254","pred":"tao:has_database_id","subj":"1254","obj":"MESH:C585161"},{"id":"A1255","pred":"tao:has_database_id","subj":"1255","obj":"MESH:C000657245"},{"id":"A1256","pred":"tao:has_database_id","subj":"1256","obj":"MESH:D003643"},{"id":"A1257","pred":"tao:has_database_id","subj":"1257","obj":"MESH:C000657245"},{"id":"A1258","pred":"tao:has_database_id","subj":"1258","obj":"MESH:D003643"},{"id":"A1259","pred":"tao:has_database_id","subj":"1259","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, selinexor is being evaluated in at least two phase 2 randomized trials in the U.S. in COVID-19 patients. One is to evaluate the activity, safety and reduction in mortality of two regimens of low-dose selinexor in patients with moderate or severe COVID-19 (NCT04355676, n = 80) and the other is to evaluate the activity of low-dose selinexor and its effect on the clinical recovery, viral load, length of hospitalization, and rate of morbidity and mortality in participants with severe COVID-19 compared to placebo (NCT04349098, n = 230)."}